WEHI finds gut cell death signal that predicts IBD relapse — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- WEHI researchers identified a 'smoldering' molecular defect in gut cells from IBD patients in which intestinal cells remain abnormally primed to die, detectable even in patients whose disease appeared well controlled.
- The study, published in Science, analyzed roughly 900 gut biopsies from 80 people with and without IBD and used patient-derived organoids — lab-grown mini-intestines — to investigate the disease directly in human cells rather than mouse models.
- The defect was already present during the earliest stages of disease activity, including in patients with clinically mild IBD, and could be detected only through detailed molecular analysis, according to study co-authors.
- Researchers tracked patients for more than two years and found that those showing stronger intestinal cell death signaling were also more likely to experience a relapse.
- The findings challenge the assumption that cell death in IBD is simply damage caused by inflammation, with the team proposing instead that abnormal cell death may help drive the disease itself — what co-author Prof. James Murphy called 'one of the first dominoes to fall.'
- Co-author Dr. Andre Samson said that even patients who become symptom-free on current treatments face a likelihood of flare or relapse, because 'IBD doesn't go away' — the persistent cell-death vulnerability sits there regardless of symptoms.
- The work was a collaboration with the Royal Melbourne Hospital, University of Melbourne, Royal Children's Hospital, Monash Institute of Pharmaceutical Sciences, the Hudson Institute and Monash University, and could eventually lead to more precise prognostic tools and treatments tailored to individual disease biology, though co-author Dr. Aysha Al-Ani cautioned no new diagnostic test or therapy is imminent.
Why it matters: Roughly 180,000 Australians live with IBD, and current treatments can induce remission but leave patients vulnerable to sudden, severe flare-ups that sometimes require hospitalization. The WEHI team's discovery of a detectable molecular signal — one that persists through symptom-free periods and correlated with relapse over a two-year follow-up — gives clinicians a concrete lead toward blood- or tissue-based tests that flag high-risk patients before they crash, while reframing cell death as a potential disease driver rather than mere collateral damage.
Ask SkimNews
